Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

키워드

참고문헌 (101)

1. Rasit Dinc, "New developments in the treatment of cutaneous leishmaniasis", Asian Pacific Journal of Tropical Medicine, 15(5), pp.196~205 (2022), Medknow[DOI]
2. Yavuz Yesilova, "Lip leishmaniasis: Clinical characteristics of 621 patients", International Journal of Critical Illness and Injury Science, 5(4), pp.265~266 (2015), Medknow[DOI]
3. Jorge Alvar, "Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action", The Lancet Global Health, 9(12), pp.e1763~e1769 (2021), Elsevier BV[DOI]
4. Jacob M. Bezemer, "Clinical criteria for Mucosal Leishmaniasis diagnosis in rural South America: A systematic literature review", PLOS Neglected Tropical Diseases, 16(8), pp.e0010621~ (2022), Public Library of Science (PLoS)[DOI]
5. Francisco Rogerlândio Martins-Melo, "Mortality and Case Fatality Due to Visceral Leishmaniasis in Brazil: A Nationwide Analysis of Epidemiology, Trends and Spatial Patterns", PLoS ONE, 9(4), pp.e93770~ (2014), Public Library of Science (PLoS)[DOI]
6. "Leishmaniasis: Situation and trend"[URL]
7. Saumya Srivastava, "Possibilities and challenges for developing a successful vaccine for leishmaniasis", Parasites & Vectors, 9(1), pp.277~ (2016), Springer Science and Business Media LLC[DOI]
8. Stefano Malvolti, "Human leishmaniasis vaccines: Use cases, target population and potential global demand", PLOS Neglected Tropical Diseases, 15(9), pp.e0009742~ (2021), Public Library of Science (PLoS)[DOI]
9. Mukesh Kumar Jha, "Development and Characterization of an Avirulent <i>Leishmania major<", i> Strain, 2020, pp.204(10), 2734~2753[DOI]
10. Carlos F. M. Silva, "Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents", Pharmaceuticals, 15(2), pp.148~ (2022), MDPI AG[DOI]
11. Wanessa Santana, "Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings", Chemistry &amp; Biodiversity, 18(9), pp.e2100336~ (2021), Wiley[DOI]
12. Ardic N, "Leishmaniasis during the increased Syrian refugee traffic", Global Journal of Infectious Diseases and Clinical Research, pp.013~019 (2018), Peertechz Publications Private Limited[DOI]
13. Rayana Carla Silva de Morais, "Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil", Experimental Parasitology, 240, pp.108338~ (2022), Elsevier BV[DOI]
14. "Leishmaniasis"[URL]
15. Fabiana Alves, "Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives", Clinical Microbiology Reviews, 31(4), pp.e00048-18~ (2018), American Society for Microbiology[DOI]
16. Wen-Wei Zhang, "A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing", Nature Communications, 11(1), pp.3461~ (2020), Springer Science and Business Media LLC[DOI]
17. Akram Miramin-Mohammadi, "Immune Responses in Cutaneous Leishmaniasis: in vitro Thelper1", Thelper2 Cy-tokine Profiles Using Live Versus Killed Leishmania major, 2021, 126~135[DOI]
18. Vanessa Carregaro, "Dual effect of Lutzomyia longipalpis saliva on Leishmania braziliensis infection is mediated by distinct saliva-induced cellular recruitment into BALB", c mice ear, 2013, pp.13(1), 102~[DOI]
19. Helou DG, "Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis", PLoS Negl Trop Dis, 15, pp.e0009627~ (2021)[DOI]
20. Subir Karmakar, "Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis", Communications Biology, 4(1), pp.929~ (2021), Springer Science and Business Media LLC[DOI]
21. Noushin Saljoughian, "Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis", Frontiers in Immunology, 5, pp.134~ (2014), Frontiers Media SA[DOI]
22. S NYLÉN, "Live <i>Leishmania<", i> promastigotes can directly activate primary human natural killer cells to produce interferon-gamma, 2003, pp.131(3), 457~467[DOI]
23. Dmitry Kopelyanskiy, "Leishmania guyanensis suppressed inducible nitric oxide synthase provoked by its viral endosymbiont", Frontiers in Cellular and Infection Microbiology, 12 (2022), Frontiers Media SA[DOI]
24. Pedro Cecílio, "Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites", Communications Biology, 5(1), pp.305~ (2022), Springer Science and Business Media LLC[DOI]
25. Hannah E. Cummings, "Cytokines and Their STATs in Cutaneous and Visceral Leishmaniasis", Journal of Biomedicine and Biotechnology, 2010, pp.1~6 (2010), Hindawi Limited[DOI]
26. Nnamdi M. Ikeogu, "Leishmania Immunity: Advancing Immunotherapy and Vaccine Development", Microorganisms, 8(8), pp.1201~ (2020), MDPI AG[DOI]
27. Natarajan G, "Pathogenesis of Leishmaniasis", pp.1~13 (2014), Springer
28. Greta Volpedo, "Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development", Frontiers in Immunology, 12, pp.748325~ (2021), Frontiers Media SA[DOI]
29. Abdellahi L, "Vaccination in leishmaniasis : a review article", Iran Biomed J, 26, pp.1~35 (2022)[DOI]
30. Bibi Razieh Hosseini Farash, "Validation of a mixture of rK26 and rK39 antigens from Iranian strain of Leishmania infantum to detect anti-Leishmania antibodies in human and reservoir hosts", Scientific Reports, 12(1), pp.10426~ (2022), Springer Science and Business Media LLC[DOI]
31. Daniel Claudio Oliveira Gomes, "Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis", Microbes and Infection, 24(2), pp.104884~ (2022), Elsevier BV[DOI]
32. Petra Sumova, "PpSP32-like protein as a marker of human exposure to Phlebotomus argentipes in Leishmania donovani foci in Bangladesh", International Journal for Parasitology, 51(12), pp.1059~1068 (2021), Elsevier BV[DOI]
33. Deepak Kumar Goyal, "Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB", c mice, 2021, pp.158, 105021~[DOI]
34. Siddhartha Kumar Bhaumik, "UDP-Gal: N-acetylglucosamine β 1–4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis", Glycoconjugate Journal, 26(6), pp.663~673 (2008), Springer Science and Business Media LLC[DOI]
35. Paula Mello De Luca, "Cutaneous Leishmaniasis Vaccination: A Matter of Quality", Frontiers in Immunology, 7, pp.151~ (2016), Frontiers Media SA[DOI]
36. Thalia Pacheco-Fernandez, "Revival of Leishmanization and Leishmanin", Frontiers in Cellular and Infection Microbiology, 11, pp.639801~ (2021), Frontiers Media SA[DOI]
37. Ostolin TL, "A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB", c mice, 2021, pp.39, 2755~2763
38. Athanasiou E, "A poly(lactic-co-glycolic)acid nanovaccine based on chimeric peptides from different Leishmania infantum proteins induces dendritic cells maturation and promotes peptide-specific IFNγ-producing CD8+ T cells essential for the protection against experimental visceral leishmaniasis", Front Immunol, 8, pp.684~ (2017)[DOI]
39. Mehdi Mohebali, "An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines", Acta Tropica, 200, pp.105173~ (2019), Elsevier BV[DOI]
40. Jorge Alvar, "Case study for a vaccine against leishmaniasis", Vaccine, 31, pp.B244~B249 (2013), Elsevier BV[DOI]
41. Fabiano Oliveira, "A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates", Science Translational Medicine, 7(290), pp.290ra90~ (2015), American Association for the Advancement of Science (AAAS)[DOI]
42. Zahedifard F, "Expression of Concern: Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen", PLOS Neglected Tropical Diseases, 15(2), pp.e0009123~ (2021), Public Library of Science (PLoS)[DOI]
43. Elaheh Davarpanah, "Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB", c mice, 2020, pp.14(1), e0007939~[DOI]
44. Graham F Mitchell, "VACCINATION AGAINST CUTANEOUS LEISHMANIASIS IN MICE USING NONPATHOGENIC CLONED PROMASTIGOTES OF <i>LEISHMANIA MAJOR<", i> AND IMPORTANCE OF ROUTE OF INJECTION, 1984, pp.62(2), 145~153[DOI]
45. Reginald M. Gorczynski, "Immunization of susceptible BALB", c mice against Leishmania braziliensis,, 1985, pp.94(1), 11~20[DOI]
46. D. RIVIER, "Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge", Parasite Immunology, 15(2), pp.75~84 (1993), Wiley[DOI]
47. P B Kimsey, "An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB", c mice against infection with virulent L. major, 1993, pp.61(12), 5205~5213[DOI]
48. Hamid Daneshvar, "<i>Leishmania mexicana<", i>and<i>Leishmania major:<, The Journal of Infectious Diseases, pp.2003, 187(10)[DOI]
49. Jacinto Convit, "Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report", Memórias do Instituto Oswaldo Cruz, 99(1), pp.57~62 (2004), FapUNIFESP (SciELO)[DOI]
50. Márcio Sobreira Silva Araújo, "Despite Leishvaccine and Leishmune® trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis", Vaccine, 26(18), pp.2211~2224 (2008), Elsevier BV[DOI]
51. Hossein Rezvan, "Leishmania vaccines entered in clinical trials: A review of literature", International Journal of Preventive Medicine, 10(1), pp.95~ (2019), Medknow[DOI]
52. J. Convit, "Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–1999", Transactions of the Royal Society of Tropical Medicine and Hygiene, 97(4), pp.469~472 (2003), Oxford University Press (OUP)[DOI]
53. Ali Khamesipour, "Therapeutic vaccines for leishmaniasis", Expert Opinion on Biological Therapy, 14(11), pp.1641~1649 (2014), Informa Healthcare[DOI]
54. Rita Velez, "Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy", Tropical Medicine &amp; International Health, 25(5), pp.540~557 (2020), Wiley[DOI]
55. G.P. Borja-Cabrera, "Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil", Vaccine, 26(39), pp.4991~4997 (2008), Elsevier BV[DOI]
56. "CaniLeish: canine vaccine against Leishmania infantum adjuvanted"[URL]
57. Javier Moreno, "Use of a LiESP", QA-21 Vaccine (CaniLeish) Stimulates an Appropriate Th1-Dominated Cell-Mediated Immune Response in Dogs, 2012, pp.6(6), e1683~[DOI]
58. N. Parody, "Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb", c mice from infection, 2004, pp.26(6-7), 283~293[DOI]
59. Sami Ben Hadj Ahmed, "A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major", Vaccine, 22(13-14), pp.1631~1639 (2004), Elsevier BV[DOI]
60. Olobo JO, "Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein'(gp63)", Vet Parasitol, 60, pp.199~212 (1995)[DOI]
61. Sanjay Gurunathan, "Vaccination with DNA Encoding the Immunodominant LACK Parasite Antigen Confers Protective Immunity to Mice Infected with Leishmania major", Journal of Experimental Medicine, 186(7), pp.1137~1147 (1997), Rockefeller University Press[DOI]
62. Yang DM, "Oral Salmonella typhimurium(AroA-)vaccine expressing a major Leishmanial surface protein(gp63)preferentially induces T helper 1 cells and protective immunity against leishmaniasis", J Immunol, 145, pp.2281~2285 (1990)
63. D McMahon-Pratt, "Recombinant vaccinia viruses expressing GP46", M-2 protect against Leishmania infection, 1993, pp.61(8), 3351~3359[DOI]
64. Champsi J, "Membrane glycoprotein M-2 protects against Leishmania amazonensis infection", Infect Immun, 56, pp.3272~3279 (1988)[DOI]
65. E Handman, "Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response", Infection and Immunity, 63(11), pp.4261~4267 (1995), American Society for Microbiology[DOI]
66. Wania Renata Santos, "Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine", Vaccine, 21(32), pp.4668~4676 (2003), Elsevier BV[DOI]
67. Rajeev Nagill, "Vaccine candidates for leishmaniasis: A review", International Immunopharmacology, 11(10), pp.1464~1488 (2011), Elsevier BV[DOI]
68. Rhea N Coler, "From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE", Clinical &amp; Translational Immunology, 4(4), pp.e35~ (2015), Wiley[DOI]
69. Gillespie PM, "Status of vaccine research and development of vaccines for leishmaniasis", Vaccine, 34, pp.2992~2995 (2016)[DOI]
70. Jaya Chakravarty, "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis", Vaccine, 29(19), pp.3531~3537 (2011), Elsevier BV[DOI]
71. Malcolm S. Duthie, "The development and clinical evaluation of second-generation leishmaniasis vaccines", Vaccine, 30(2), pp.134~141 (2012), Elsevier BV[DOI]
72. Sreenivas Gannavaram, "Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis – Discovery and Implications", Frontiers in Immunology, 5, pp.241~ (2014), Frontiers Media SA[DOI]
73. Barbara Papadopoulou, "Reduced Infectivity of a<i>Leishmania donovani<", i>Biopterin Transporter Genetic Mutant and Its Use as an Attenuated Strain for Vaccination, 2002, pp.70(1), 62~68[DOI]
74. Ricardo Silvestre, "SIR2-Deficient <i>Leishmania infantum<", i> Induces a Defined IFN-γ, The Journal of Immunology, pp.2007, 179(5)[DOI]
75. Javier Carrión, "Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation", Parasites &amp; Vectors, 4(1), pp.150~ (2011), Springer Science and Business Media LLC[DOI]
76. Anirban Ghosh, "Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response", Vaccine, 19(23-24), pp.3169~3178 (2001), Elsevier BV[DOI]
77. Ranadhir Dey, "Live Attenuated <i>Leishmania donovani<", i> p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB, The Journal of Immunology, pp.2013, 190(5)[DOI]
78. Patricia S. Walker, "Genetic Immunization with Glycoprotein 63 cDNA Results in a Helper T Cell Type 1 Immune Response and Protection in a Murine Model of Leishmaniasis", Human Gene Therapy, 9(13), pp.1899~1907 (1998), Mary Ann Liebert Inc[DOI]
79. Muli Joshua, "Development of Leishmania vaccines: predicting the future from past and present experience", The Journal of Biomedical Research, 27(2), pp.85~102 (2013), Journal of Biomedical Research[DOI]
80. Thuntawat Aunguldee, "Immunogenicity and potential protection of DNA vaccine of Leishmania martiniquensis against Leishmania infection in mice", The Journal of Infection in Developing Countries, 15(09), pp.1328~1338 (2021), Journal of Infection in Developing Countries[DOI]
81. Sima Rafati, "Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB", c mice, 2008, pp.118(3), 393~401[DOI]
82. Pragya Prasanna, "Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis – A review", Biomedicine &amp; Pharmacotherapy, 141, pp.111920~ (2021), Elsevier BV[DOI]
83. "University of York. A study to assess the safety, efficacy and immunogenicity of Leishmania vaccine ChAd63-KH in PKDL"[URL]
84. Tahereh Taheri, "Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development", Clinical Investigation, 3(11), pp.1023~1044 (2013), OMICS Publishing Group[DOI]
85. Greta Volpedo, "From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection", Expert Review of Vaccines, 20(11), pp.1431~1446 (2021), Informa UK Limited[DOI]
86. Pedro Cecílio, "Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis", PLOS Neglected Tropical Diseases, 11(11), pp.e0005951~ (2017), Public Library of Science (PLoS)[DOI]
87. Mohamed Osman, "A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH", PLOS Neglected Tropical Diseases, 11(5), pp.e0005527~ (2017), Public Library of Science (PLoS)[DOI]
88. Rashmirekha Pati, "Nanoparticle Vaccines Against Infectious Diseases", Frontiers in Immunology, 9, pp.2224~ (2018), Frontiers Media SA[DOI]
89. Maritsa Margaroni, "Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble &lt;em&gt;Leishmania&lt;", em&gt; antigens and modified with a TNF&amp;alpha;-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis, 2017, pp.12, 6169~6184[DOI]
90. Yasaman TASLIMI, "Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leish-maniasis in Syrian Hamster as Preliminary Study", Iranian Journal of Parasitology, 15, pp.383~392 (2020), Knowledge E[DOI]
91. Daniela P. Lage, "A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection", npj Vaccines, 5(1), pp.75~ (2020), Springer Science and Business Media LLC[DOI]
92. Marcus Vinícius Alves-Silva, "The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice", Frontiers in Immunology, 10, pp.724~ (2019), Frontiers Media SA[DOI]
93. Stephan Klatt, "Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host", PLOS Neglected Tropical Diseases, 13(7), pp.e0007424~ (2019), Public Library of Science (PLoS)[DOI]
94. Jairo Alfonso Mendoza-Roldan, "Detection of Leishmania tarentolae in lizards, sand flies and dogs in southern Italy, where Leishmania infantum is endemic: hindrances and opportunities", Parasites &amp; Vectors, 14(1), pp.461~ (2021), Springer Science and Business Media LLC[DOI]
95. Marie Breton, "Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis", Infection and Immunity, 73(10), pp.6372~6382 (2005), American Society for Microbiology[DOI]
96. Mirosława Panasiuk, "Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies", Microbial Cell Factories, 20(1), pp.186~ (2021), Springer Science and Business Media LLC[DOI]
97. Anna Paula V. Moura, "Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against <i>Leishmania<", i> Infection, 2017, pp.3(9), 1026~1031[DOI]
98. Ans De Beuckelaer, "Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines", Trends in Molecular Medicine, 23(3), pp.216~226 (2017), Elsevier BV[DOI]
99. Leroy Versteeg, "Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections", Vaccines, 7(4), pp.122~ (2019), MDPI AG[DOI]
100. Malcolm S. Duthie, "Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani", Frontiers in Immunology, 9, pp.2420~ (2018), Frontiers Media SA[DOI]
101. Malcolm S. Duthie, "Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs", Pathogens, 11(11), pp.1259~ (2022), MDPI AG[DOI]

관련 논문AI추천